Seòmar agus comataidhean

The opening of a Scottish Government office in Warsaw is currently under review given ongoing budget pressures.

Significant Adverse Event Reviews (SAERs) are conducted at a local level within each NHS Health Board. NHS Boards are required to notify Healthcare Improvement Scotland on a monthly basis of the number of SAERs that have been commissioned, including the event type and specialty. HIS recently reviewed and published an updated version of A national framework for reviewing and learning from adverse events in NHS Scotland: February 2025 – Healthcare Improvement Scotland in February this year. This provides templates to support NHS Health Boards to consistently report and learn from SAERs. The Scottish Government does not monitor NHS Boards responses to SAERs.

The Scottish Government is committed to improving life expectancy and tackling health inequalities across Scotland. The recently published Population Health Framework, a joint publication by the Scottish Government and COSLA, highlights that the circumstances and environments in which people are born, grow up, live, work and age – known as the building blocks of health – are the most influential factors shaping health outcomes.

The Framework’s supporting evidence paper notes that Scotland has experienced a decline in healthy life expectancy – the number of years people can expect to live in good health – alongside a stalling of improvements in mortality rates after decades of steady progress. These trends are associated with several major factors: the UK Government’s austerity policies during the 2010s, Brexit, the COVID-19 pandemic, and the ongoing cost-of-living crisis. Together, these influences have weakened the building blocks of health, widened existing inequalities, and exacerbated Scotland’s longstanding disparities in income, wealth, and power.

In response, the Population Health Framework sets out a whole-system cross-government and cross-sector approach centred on prevention. This approach builds on existing Scottish Government actions, including initiatives on diet and healthy weight, and efforts to tackle child poverty. Through this approach, the Scottish Government aims to raise overall life expectancy while closing the gap between the most deprived 20% of communities and the national average by 2035.

I refer the member to the answer to question S6W-37406 on 19 May 2025. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

The Scottish Government has increased the Scottish Fire and Rescue Service (SFRS) capital budget by £10.5 million in 2024-25 and by a further £4 million in 2025-26, bringing the total annual budget to £47 million. SFRS is currently conducting a Service Delivery Review to ensure that investment in its estate, fleet and equipment is focussed where it is needed most.

All wholetime fire stations have some form of segregated washing facilities for staff and the Scottish Fire and Rescue Service (SFRS) estates strategy ensures all premises are risk assessed and that suitable alternative washing facility arrangements and mitigations are implemented. SFRS recognises the need for investment in dignified facilities and for contaminant control measures and prioritises its budget accordingly, for example as part of ongoing work. SFRS has recently upgraded facilities at Galashiels, Newcraighall, McDonald Road, Edinburgh and Inverness.

There are studies that show a developing evidence base for the use of mifepristone in breast cancer prevention as outlined in the opinion piece in The Lancet.

The regulation for the licensing, safety and efficacy of medicines is currently reserved to the UK Government and is the responsibility of the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA is also responsible for enabling innovation, research and development that is beneficial to public health, including overseeing clinical trials which underpin evidence based practice. Clinical trials are an important part of the pathway by which a new medicinal product or a new use of an existing medicine can be marketed for use as a new treatment.

Before a medicine can be marketed, a pharmaceutical company must be able to demonstrate its safety, quality and efficacy. A marketing authorisation (sometimes called a licence) is granted to market a medicine for a specific indication (condition) and not to the medicine itself. The decision to apply for a marketing authorisation for a new medicine or new indication is for a pharmaceutical company to make. In doing so they must include data from clinical trials and other studies demonstrating the quality, safety and efficacy of the medicine. After detailed assessment and providing the data is satisfactory, a marketing authorisation may be granted.

Whilst Scottish Government sets the strategic policy direction for the NHS in Scotland, operational matters including staffing are the responsibility NHS Boards. NHS Boards take account of national, regional, and local priorities, and we expect NHS boards to plan and provide safe, effective, and high-quality care, in line with their statutory service provision and workforce planning responsibilities.

To help address recognised workforce pressures, Scottish Government continues to invest heavily in radiology training. Scottish Government is currently funding around 190 specialty training places in clinical radiology, including 78 extra places which have been added since 2014. This enables doctors to train and enter the workforce following completion of training - which takes a minimum of 5 years. Clinical radiology specialty training programmes have been filled at 100% in Scotland from 2014 to 2024, with 230 resident doctors successfully completing training in this period.

To further support a coordinated response to pressures in cancer services, Scottish Government commissioned the National Oncology Coordination Group. This group considers real-time assessments and develops proactive risk mitigation proposals aligned with the strategic aims for cancer. This collaborative approach across NHS Boards in Scotland is ensuring that services can deliver for people with cancer.

How the recommendations are taken forward will be determined following consultation with stakeholders, including NHS Boards and OSCR. Consultation will ensure no unintended consequences as well as appropriate consideration of capacity, as significant work will be involved for both for the Scottish Government and for Health Boards. The timing of that consultation has yet to be determined.

In the meantime, funds remain available to be directed in accordance with the charities’ purpose, and taking account any restricted funds.

It is also important to note that neither OSCR's inquiry nor the Independent Review indicated that there are widespread issues in the decisions being made about the use of NHS Endowments’ charitable funds.

Our position is unchanged on waiting times – by March 2026 no one will wait more than 12 months for a new outpatient appointment or inpatient/daycase treatment.

We are investing more than £110 million this year to cut waits, and we expect to see the full impact of our targeted funding in the coming months. This targeted funding is expected to deliver more than 213,000 additional procedures and appointments this year.

Our plan is clearly working with a record number of hip and knee operations last year and the highest level of operations performed in July since February 2020.